Can CRSP's In Vivo Pipeline Aid Long-Term Growth Beyond Casgevy?

CRISPR Therapeutics (CRSP), building on the success of its approved ex vivo therapy Casgevy, is now prioritizing its in vivo pipeline, with early Phase I data for CTX310 demonstrating significant reductions of up to 86% in LDL and 82% in triglycerides. The company aims to expand this pipeline by advancing two additional in vivo programs into clinical studies by late 2025, signaling a strategic focus on diversifying beyond Casgevy. While CRSP shares have outperformed, rallying 34.7% year-to-date and trading at a price-to-book discount to the industry, its in vivo candidates remain in early development, and it faces growing competition from peers like Beam Therapeutics and Intellia Therapeutics.

Analysis

CRISPR Therapeutics is strategically pivoting from its initial success with the commercialized ex vivo therapy, Casgevy, toward developing a broader in vivo pipeline. This shift is substantiated by encouraging early-stage data from its CTX310 program, which demonstrated dose-dependent peak reductions of up to 86% in LDL and 82% in triglycerides in a Phase I study. The company plans to further de-risk its reliance on Casgevy, which is co-commercialized with Vertex in a 60:40 profit-sharing agreement, by advancing two additional in vivo candidates for hypertension and acute hepatic porphyria into clinical trials by the end of 2025. Despite this promising long-term strategy, which has driven the stock up 34.7% year-to-date, significant risks remain. The in vivo pipeline is nascent, and Casgevy faces immediate competition from incumbent chronic therapies. Furthermore, the gene-editing landscape is becoming increasingly crowded with competitors like Beam Therapeutics and Intellia Therapeutics also developing clinical-stage candidates. Financially, the outlook is mixed; while the stock trades at a price-to-book discount to the industry at 2.68, analyst loss-per-share estimates for 2025 have widened from $5.67 to $6.38, likely reflecting increased R&D investment, though estimates for 2026 have narrowed, suggesting a potential future inflection point.

Key Decisions for Investors

• Investors should consider the long-term potential of the in vivo platform, validated by the promising early CTX310 data, but must weigh this against the significant clinical and commercial risks of an early-stage pipeline.
• Monitor the commercial ramp-up of Casgevy and competitive developments from Beam Therapeutics and Intellia Therapeutics, as these will be key determinants of near- to mid-term performance.
• The widening 2025 loss estimates suggest increased near-term cash burn, but the narrowing 2026 estimates and valuation discount to the industry could present a strategic entry point for investors with a high risk tolerance and a long-term investment horizon.